Latest news with #MerckCo
Globe and Mail
14-07-2025
- Business
- Globe and Mail
Precision Diagnostics & Medicine Market worth $246.66 billion by 2029
"Key players in the Precision diagnostic market include F. Hoffman La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), and Guardant Health (US) among others and key players in precision medicine market include Merck Co, Inc. (US), Gilead Sciences (US), AstraZeneca (UK), Novartis AG (Switzerland), among others." Browse 416 market data Tables and 92 Figures spread through 445 Pages and in-depth TOC on "Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication (Oncology, Neurology, Immunology), Therapeutic Products (Inhibitors, mAbs, CGT), Indication (Oncology, Rare Disease, Infectious) - Global Forecast to 2029 The report " Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication (Oncology, Neurology, Immunology), Therapeutic Products (Inhibitors, mAbs, CGT), Indication (Oncology, Rare Disease, Infectious) - Global Forecast to 2029", is expected to reach USD 246.66 billion by 2029 from USD 145.53 billion in 2024, growing at a CAGR of 11.1% Factors such as the increasing integration of AI and ML for the development of advanced precision diagnostics and therapeutic solutions supported by the rising collaboration and investment by major pharmaceutical companies for the development of precision medicine and biomarker discovery drive the growth of the market. Moreover, the increasing demand for direct-to-consumer testing owing to the growing awareness of patients towards their health and the convenience offered by these tests supports the adoption of precision diagnostics. Additionally, the expanding focus of pharmaceutical companies on the development of precision solutions for other diseases such as neurodegenerative disorders and autoimmune diseases and the integration of wearable technology to enhance healthcare offers growth opportunities for players operating in the precision medicine market. However, factors such as the high cost of precision healthcare and the challenges related to the integration and management of big data in precision solution development restrain the growth of the market. Browse 416 market data Tables and 92 Figures spread through 445 Pages and in-depth TOC on "Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication (Oncology, Neurology, Immunology), Therapeutic Products (Inhibitors, mAbs, CGT), Indication (Oncology, Rare Disease, Infectious) - Global Forecast to 2029"View detailed Table of Content here - The monoclonal antibodies segment accounted for the largest share of the Precision Medicine Market, by product, during the forecast period. Based on products, the precision medicine market is divided into inhibitor drugs, monoclonal antibodies, cell and gene therapy, antiviral and anti-retroviral drugs, and other therapeutic products. The large share of the monoclonal antibodies products segment can be attributed to the fact that a large number of the approved precision therapies are monoclonal antibodies. This large share of this segment is also supported by the ongoing approvals for monoclonal antibody drugs for various cancers and other diseases highlighting a focus of pharmaceutical companies on the development of monoclonal antibodies as precision medicines. The oncology subsegment accounted for the largest share of the precision diagnostics market's indication segment in 2023 Based on indication, the precision diagnostics market is segmented into oncology, neurology, immunology, and other indications. The oncology segment accounted for the largest share of the precision diagnostics market by indication in 2023. The large share of this segment is attributed to the increase in cancer cases globally, supported by rising demand for diagnostic tests offering early and accurate cancer diagnosis. For this reason, life science companies are increasingly investing and collaborating to develop advanced oncology diagnostic tests. This dominance is expected to continue throughout the forecast period as major players are developing new technologies for better oncology diagnosis. Asia Pacific is registered as the fastest-growing region of the Precision diagnostics market in 2023. The Precision medicine market is divided into five regions, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2023, North America held the largest share of the precision diagnostics market, followed by Europe. Aisa Pacific registered the highest CAGR growth within the precision diagnostics market during the forecast period. The expansion of key diagnostic players in the region followed by favorable policies supporting the larger adoption of precision medicine is a supporting factor. Additionally, there is a greater awareness about personalized approach to treatments in these developed regions compared to the developing/ emerging economies. Key players in the Precision diagnostic market include F. Hoffman La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), and Guardant Health (US) among others and key players in precision medicine market include Merck Co, Inc. (US), Gilead Sciences (US), AstraZeneca (UK), Novartis AG (Switzerland), among others. Don't miss out on business opportunities in Precision Diagnostics & Medicine Market. Speak to our analyst and gain crucial industry insights that will help your business grow.
Wall Street Journal
09-07-2025
- Business
- Wall Street Journal
Merck to Buy Verona Pharma in $10 Billion Deal
Merck & Co. has struck a roughly $10 billion deal to buy Verona Pharma, bolstering its lineup with the chronic obstructive pulmonary disease treatment Ohtuvayre as it braces for the 2028 loss of patent exclusivity for the blockbuster cancer drug Keytruda. Merck on Wednesday said it will acquire Verona for $107 per American depository share, a 23% premium to Tuesday's closing price of $86.86 for the London-based company.
Yahoo
24-06-2025
- Business
- Yahoo
Growing Shifts Toward Targeted Therapies and Immunotherapy Over Traditional Methods
The global brain cancer treatment market is rapidly evolving, driven by the increasing incidence of brain cancer and advancements in medical technology focusing on personalized medicine. With immunotherapies and genetically tailored treatments gaining traction, the market is shifting from traditional methods to more targeted solutions. The discovery of genetic markers facilitates precision medicine strategies, marking significant milestones with new biologics and therapies. North America leads, supported by its robust healthcare infrastructure. However, the market faces challenges such as high therapy costs. Key players like Merck & Co., Novartis, and Genentech dominate the competitive landscape. Dublin, June 24, 2025 (GLOBE NEWSWIRE) -- The "Brain Cancer Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" report has been added to offering. The market for brain cancer treatments is transitioning from traditional methods (surgery, chemotherapy) to more targeted therapies and immunotherapy approaches. This shift is fuelled by the discovery of genetic markers and biomarkers associated with brain tumours, allowing for the development of precision medicine strategies. The approval of new biologics and immunotherapies represents a significant milestone in the treatment landscape for brain factors driving this market include the increasing incidence of brain cancer, advancements in medical technology, and the growing focus on personalized medicine. Brain cancer, one of the most challenging types of cancer to treat, requires innovative solutions due to its complex cancer involves abnormal cell growth in the brain that disrupts normal brain function. Treatments are becoming more sophisticated, targeting the tumour directly while preserving healthy brain tissue. Immunotherapies and personalized treatments tailored to the patient's genetic makeup are gaining traction in this America holds a dominant position in the global brain cancer market, driven by its advanced healthcare infrastructure, high diagnosis rates, and strong presence of key pharmaceutical companies. How Can This Report Add Value to an Organization?Product/Innovation Strategy: This report provides valuable insights for pharmaceutical companies looking to innovate in brain cancer treatments, focusing on targeted therapies, immunotherapies, and precision medicine. It helps identify emerging trends in brain cancer treatment and potential gaps in the Strategy: For pharmaceutical companies and healthcare providers, understanding current market dynamics, emerging trends, and key competitors is essential. This report equips stakeholders with the tools to assess market opportunities and stay competitive in the global brain cancer Market Players and Competition SynopsisThe companies profiled in this report are selected based on expert insights, evaluating company coverage, product portfolio, and market penetration. Leading players in the global brain cancer market include pharmaceutical companies and service providers who hold substantial shares of the - Drivers and Limitations The global brain cancer market is driven by several key factors: Increasing incidence of brain cancer Advancements in medical technology The increasing focus on precision medicine Limitations: High cost of therapies Some of the prominent names established in this market are: Merck & Co., Inc. Novartis AG Genentech Orbus Therapeutics VBL Therapeutics DNAtrix Key Topics Covered: 1. Global Brain Cancer Market: Industry Outlook1.1 Market Overview and Ecosystem1.2 Epidemiological Analysis of Brain Cancer1.2.1 By Region1.3 Market Trends1.4 Clinical Trials1.4.1 By Phase1.5 Regulatory Landscape Analysis1.5.1 Legal Requirement and Framework in U.S.1.5.2 Legal Requirement and Framework in E.U.1.5.3 Legal Requirement and Framework in Asia-Pacific1.5.4 Legal Requirement and Framework in Rest-of-the-World1.6 Market Dynamics1.6.1 Impact Analysis1.6.2 Market Drivers1.6.3 Market Restraints1.6.4 Market Opportunities2. Global Brain Cancer Market, by Region, $Million, 2023-20352.1 North America2.1.1 Key Findings2.1.2 Market Dynamics2.1.3 Market Sizing and Forecast2.1.3.1 North America Brain Cancer Market (by Country)2.1.3.1.1 U.S.2.1.3.1.2 Canada2.2 Europe2.2.1 Key Findings2.2.2 Market Dynamics2.2.3 Market Sizing and Forecast2.2.3.1 Europe Brain Cancer Market (by Country)2.2.3.1.1 Germany2.2.3.1.2 France2.2.3.1.3 Italy2.2.3.1.4 U.K.2.2.3.1.5 Rest-of-Europe2.3 Asia-Pacific2.3.1 Key Findings2.3.2 Market Dynamics2.3.3 Market Sizing and Forecast2.3.3.1 Asia-Pacific Brain Cancer Market (by Country)2.3.3.1.1 China2.3.3.1.2 Japan2.3.3.1.3 India2.3.3.1.4 Rest-of-Asia-Pacific2.4 Rest-of-the-World2.4.1 Key Findings2.4.2 Market Dynamics2.4.3 Market Sizing and Forecast3. Global Brain Cancer Market - Competitive Benchmarking and Company Profiles3.1 Competitive Landscape3.1.1 Key Strategies and Developments by Company3.1.1.1 Funding Activities3.1.1.2 Mergers and Acquisitions3.1.1.3 Regulatory Approvals3.1.1.4 Partnerships, Collaborations and Business Expansions3.1.2 Key Developments Analysis3.2 Company Profiles3.2.1 Company Overview3.2.2 Product Portfolio3.2.3 Target Customers/End Users3.2.4 Key Personnel3.2.5 Analyst View4. Research MethodologyFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
18-06-2025
- Business
- Yahoo
Dividend Growth Remains a Key Priority for Merck
Merck & Co., Inc. (NYSE:MRK) is one of Best Dividend Stocks to Buy for Dependable Growth. Merck & Co., Inc. (NYSE:MRK) is one of the best dividend stocks for dependable dividend growth. The company is not only recognized for its strong pipeline but also for its consistent dividend growth. It expects approvals for up to seven cardiometabolic drugs by 2030, which could collectively bring in $15 billion in annual revenue within a few years. A close-up of a person's hand holding a bottle of pharmaceuticals. Overall, Merck & Co., Inc. (NYSE:MRK) believes it has 20 potential blockbuster drugs in development that could generate $50 billion annually over the next decade. This promising outlook supports its dividend, which has increased for 14 straight years. In addition, in the past five years, it has raised its payouts at an annual average rate of over 7%. With a trailing twelve-month operating cash flow of $20.8 billion and levered free cash flow of $17.1 billion, Merck & Co., Inc. (NYSE:MRK) appears well-positioned to continue raising its dividend. A payout ratio of around 45% also provides a cushion, suggesting the dividend remains safe even if earnings dip. The stock supports an attractive dividend yield of 4.14%, as of June 17. Merck & Co., Inc. (NYSE:MRK) is a global healthcare company focused on providing innovative health solutions through its range of medicines, vaccines, biologic treatments, and animal health products. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
